Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to -$6.5 million.

  • Theravance Biopharma's Cash from Operations fell 2525.02% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.7 million, marking a year-over-year increase of 222155.48%. This contributed to the annual value of -$11.5 million for FY2024, which is 5727.3% up from last year.
  • As of Q3 2025, Theravance Biopharma's Cash from Operations stood at -$6.5 million, which was down 2525.02% from $208.1 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Cash from Operations registered a high of $208.1 million during Q2 2025, and its lowest value of -$124.1 million during Q4 2022.
  • In the last 5 years, Theravance Biopharma's Cash from Operations had a median value of -$11.2 million in 2023 and averaged -$11.4 million.
  • As far as peak fluctuations go, Theravance Biopharma's Cash from Operations plummeted by 17415.47% in 2022, and later surged by 481288.79% in 2025.
  • Theravance Biopharma's Cash from Operations (Quarter) stood at -$45.2 million in 2021, then crashed by 174.15% to -$124.1 million in 2022, then soared by 99.31% to -$854000.0 in 2023, then decreased by 5.62% to -$902000.0 in 2024, then plummeted by 621.51% to -$6.5 million in 2025.
  • Its Cash from Operations stands at -$6.5 million for Q3 2025, versus $208.1 million for Q2 2025 and $43.0 million for Q1 2025.